Why It Matters
Galvanize Therapeutics is trying to ride a policy wave as Congress is actively pushing legislation like H.R. 5343 to accelerate Medicare coverage for FDA-approved breakthrough devices. The company’s lobbying directly targets these reimbursement pathways—critical for commercializing its pulsed electric field ablation technology.
Congressional hearings on examining policies to enhance seniors’ access to breakthrough medical technologies signal lawmakers recognize the coverage gap problem. H.R. 5343 would create four-year transitional Medicare coverage for breakthrough devices, while companion bill H.R. 4441 offers alternative pathways through the New Technology Add-On Payment program.
By the Numbers
Galvanize Therapeutics Inc. registered with Jeffrey J. Kimbell & Associates Inc. on September 3, 2024, deploying eight lobbyists focused on Medicare/Medicaid and health issues.
The team brings deep Senate experience: Brett Hamilton Meeks (Senate HELP Committee), Keith Shands Studdard (Senator Blackburn), and John Thomas Herzog (Senator Lamar Alexander).
Laura Holland Kemper contributes 16+ years lobbying Medicare/Medicaid policy for healthcare providers and device makers. Firm founder Jeffrey J. Kimbell brings nearly two decades of healthcare lobbying experience.
The firm previously represented medical device companies including Accuray Inc., Glaukos Corp., and LivaNova plc on reimbursement matters.
The Agenda
Galvanize Therapeutics is lobbying specifically on Medicare and Medicaid reimbursement for soft tissue ablation treatments using its pulsed electric field technology. The company targets securing favorable CMS coverage decisions and influencing soft tissue ablation device regulation.
Galvanize’s strategy aligns with the Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343), which would create four-year transitional Medicare coverage for FDA breakthrough devices, addressing the "valley of death" between approval and coverage.
The company could also benefit from the Patient Access to Innovative New Technologies Act (H.R. 4441), allowing breakthrough devices conditional Medicare reimbursement through New Technology Add-On Payments before full FDA approval.
Broader Context
Congress is aggressively addressing the years-long gap between FDA approval and Medicare coverage. House Energy and Commerce Health Subcommittee hearings signal strong committee focus on breakthrough technology access. Representatives Gus Bilirakis and Blake Moore champion House breakthrough legislation, while Senators Alex Padilla and Todd Young introduced the Senate companion, highlighting the average 5.7-year coverage delay.
The competitive landscape includes the Medical Device Manufacturers Association lobbying on FDA processes and market access barriers. Galvanize’s focus on soft tissue ablation distinguishes it from broader industry advocacy while benefiting from overall policy momentum toward faster coverage decisions.
Between The Lines
H.R. 5343 has advanced with strong bipartisan support. House Ways and Means Committee hearings on Medicare Advantage are relevant, given MA plans now cover over half of Medicare beneficiaries and control coverage decisions.
Competitive Landscape
Galvanize enters a competitive space where Signifier Medical Technologies Ltd. actively lobbied on device coverage in 2024 but terminated engagement at year’s end. The Medical Device Manufacturers Association provides ongoing sector-wide advocacy, creating a favorable environment for Galvanize’s specialized soft tissue ablation strategy.
The Bottom Line
Galvanize’s success requires navigating legislative action and CMS’s limited expedited coverage program, which accepts approximately five devices annually. With experienced healthcare lobbyists and targeted reimbursement focus, Galvanize is positioning itself to influence ongoing policy debates that could directly benefit its pulsed electric field technology commercialization.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article